Spark: A Big Win for Gene Therapy. So Why Is It Falling?

Shares of Spark Therapeutics are down today, despite winning the recommendation of a FDA advisory panel for its experimental gene therapy.
Source: Barrons

Leave a Reply

Your email address will not be published.

You may use these HTML tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <strike> <strong>